Foghorn Therapeutics Stock News

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases

Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -24.53% and 68.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the sto

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically det

Foghorn has partnering deals with major big pharma. They have a novel technology which no one else seems to have.

CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically dete

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ: FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myel

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically de

Foghorn Therapeutics Inc. (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the

The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in

Foghorn Therapeutics Inc. (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revision

Equities research analysts expect that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will post sales of $330,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Foghorn Therapeutics earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $150,000.00. The firm is scheduled to issue []

Analysts expect Foghorn Therapeutics Inc. (NASDAQ:FHTX) to post ($0.29) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Foghorn Therapeutics earnings, with the lowest EPS estimate coming in at ($0.72) and the highest estimate coming in at $0.56. The business is scheduled to report its next []

Brokerages predict that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will announce $330,000.00 in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Foghorn Therapeutics earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $150,000.00. The business is expected to announce its next quarterly earnings []

Equities analysts predict that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will announce earnings per share of ($0.29) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Foghorn Therapeutics earnings, with the highest EPS estimate coming in at $0.56 and the lowest estimate coming in at ($0.72). The business is expected to []